Sector News

Merck KGaA on track to complete Sigma-Aldrich acquisition

September 28, 2015
Life sciences

( – German drug maker Merck KGaA said it is on track to complete the acquisition of life science company Sigma-Aldrich Corp. and is is the process of fulfilling antitrust commitments to the European Commission.

The acquisition is expected to close within the next two months. Merck in August had forecast to complete the transaction in the third quarter.

The planned acquisition of Sigma-Aldrich for about $17 billion or 13.1 billion euros was announced in September 2014.

Merck said negotiations with potential buyers are in the final stage to sell parts of Sigma-Aldrich’s solvents and inorganics business. This was a condition set for obtaining European Commission approval. Merck on August 11 announced that it had obtained all other necessary antitrust approvals.

Merck added that once a binding agreement has been signed, the European Commission needs to approve the buyer before Merck can proceed with the completion of the Sigma-Aldrich acquisition.

Sigma-Aldrich shareholders approved the merger with Merck in December 2014. Merck has also completed its capital markets activities to finance the transaction with the placement of a 2.1 billion euro bond at the end of August.

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.